Compare Godaddy Inc (GDDY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Godaddy Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GDDY | XBI | |
|---|---|---|
Market Cap | $13.07B | $10.11B |
Volume | 1,831,274 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $135.18 | $169.55 |
52-Week Low | $75.07 | $104.99 |
Typical Hold Time | 64 Days | 38 Days |
Enterprise Value | $15.75B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $103.19, up 6.15% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $4.95B revenue, 17.83% net margin, and consistent earnings beats in recent quarters. However, the stock faces headwinds from multiple securities class action lawsuits alleging misrepresentation of domain contract terms during September 2025-February 2026 period, creating significant legal overhang despite positive operational performance.
While GoDaddy maintains strong profitability and analyst support (58% buy ratings), the legal challenges present substantial near-term risk. The stock trades above consensus price target of $96.20, suggesting limited upside potential. Investors must weigh robust financial performance against litigation uncertainties that could impact shareholder value through settlements or reputational damage.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
